Chronic dysfunction of the endothelium is associated with mortality in acute coronary syndrome patients

Thrombosis Research

Volumn 131, Issue 3, 2013, Pages 198-203

  Hyseni, Agon ^a   Roest, Mark ^a   Braun, Siegmund L ^b   Barendrecht, Arjan D ^a   De Groot, Philip G ^a   Ndrepepa, Gjin ^b   Kastrati, Adnan ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BIOLOGICAL MARKER; CLOPIDOGREL; OSTEOPROTEGERIN; RANTES; THROMBOSPONDIN 1; VON WILLEBRAND FACTOR;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR MORTALITY; CELL ACTIVATION; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROBABILITY; THROMBOCYTE ACTIVATION;

ACUTE CORONARY SYNDROME; AGED; BLOOD PLATELETS; CHEMOKINE CCL5; CORONARY VESSELS; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; OSTEOPROTEGERIN; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; THROMBOSPONDIN 1; TIME FACTORS;

EID: 84875260038     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2012.12.001     Document Type: Article

References (46)

1. J.P. Bassand, C.W. Hamm, D. Ardissino, E. Boersma, A. Budaj, and F. Fernandez-Aviles Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes Eur Heart J 28 2007 1598 1660
2. S.C. Smith Jr., J. Allen, S.N. Blair, R.O. Bonow, L.M. Brass, and G.C. Fonarow AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute Circulation 113 2006 2363 2372
3. K.A. Eagle, M.J. Lim, O.H. Dabbous, K.S. Pieper, R.J. Goldberg, and F. Van de Werf A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry JAMA 291 2004 2727 2733
4. K.A. Fox, K.A. Eagle, J.M. Gore, P.G. Steg, and F.A. Anderson The Global Registry of Acute Coronary Events, 1999 to 2009-GRACE Heart 96 2010 1095 1101
5. T. Toyo-oka, T. Aizawa, N. Suzuki, Y. Hirata, T. Miyauchi, and W. Shin Increased plasma level of endothelin-1 and coronary spasm induction in patients with vasospastic angina pectoris Circulation 83 1991 476 483
6. S.G. Thompson, J. Kienast, S.D. Pyke, F. Haverkate, and J.C. van de Loo Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group N Engl J Med 332 1995 635 641
7. J.H. Jansson, T.K. Nilsson, and O. von Johnson Willebrand factor, tissue plasminogen activator, and dehydroepiandrosterone sulphate predict cardiovascular death in a 10 year follow up of survivors of acute myocardial infarction Heart 80 1998 334 337
8. J.H. Jansson, T.K. Nilsson, and O. von Johnson Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death Br Heart J 66 1991 351 355
9. E. Falk, P.K. Shah, and V. Fuster Coronary plaque disruption Circulation 92 1995 657 671
10. A. Yamashita, T. Sumi, S. Goto, Y. Hoshiba, K. Nishihira, and R. Kawamoto Detection of von Willebrand factor and tissue factor in platelets-fibrin rich coronary thrombi in acute myocardial infarction Am J Cardiol 97 2006 26 28
11. N. Methia, P. Andre, C.V. Denis, M. Economopoulos, and D.D. Wagner Localized reduction of atherosclerosis in von Willebrand factor-deficient mice Blood 98 2001 1424 1428
12. A.O. Spiel, J.C. Gilbert, and B. von Jilma Willebrand factor in cardiovascular disease: focus on acute coronary syndromes Circulation 117 2008 1449 1459
13. R. Abbate, G. Cioni, I. Ricci, M. Miranda, and A.M. Gori Thrombosis and acute coronary syndrome Thromb Res 129 2012 235 240
14. M. Gawaz, H. Langer, and A.E. May Platelets in inflammation and atherogenesis J Clin Invest 115 2005 3378 3384
15. U. Derhaschnig, and B. Jilma Assessment of platelets and the endothelium in patients presenting with acute coronary syndromes-is there a future? Thromb Haemost 102 2009 1144 1148
16. A. Schömig, J. Mehilli, H. Holle, K. Hösl, D. Kastrati, and J. Pache Statin treatment following coronary artery stenting and one-year survival J Am Coll Cardiol 40 2002 854 861
17. C. Ceconi, K.M. Fox, W.J. Remme, M.L. Simoons, M. Bertrand, and G. Parrinello ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT Cardiovasc Res 73 2007 237 246
18. R. Ferrari, G. Guardigli, and C. Ceconi Secondary prevention of CAD with ACE inhibitors: a struggle between life and death of the endothelium Cardiovasc Drugs Ther 24 2010 331 339
19. E.J. Armstrong, D.A. Morrow, and M.S. Sabatine Inflammatory biomarkers in acute coronary syndromes: part II: acute-phase reactants and biomarkers of endothelial cell activation Circulation 113 2006 e152 e155
20. C.J. van Schooten, C.V. Denis, T. Lisman, J.C. Eikenboom, F.W. Leebeek, and J. Goudemand Variations in glycosylation of von Willebrand factor with O-linked sialylated T antigen are associated with its plasma levels Blood 109 2007 2430 2437
21. S. Kamath, A.D. Blann, B.S. Chin, F. Lanza, B. Aleil, and J.P. Cazenave A study of platelet activation in atrial fibrillation and the effects of antithrombotic therapy Eur Heart J 23 2002 1788 1795
22. K. Muller, S. Aichele, M. Herkommer, B. Bigalke, K. Stellos, and P. Htun Impact of inflammatory markers on platelet inhibition and cardiovascular outcome including stent thrombosis in patients with symptomatic coronary artery disease Atherosclerosis 213 2010 256 262
23. P. von Hundelshausen, K.S. Weber, Y. Huo, A.E. Proudfoot, P.J. Nelson, and K. Ley RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium Circulation 103 2001 1772 1777
24. A. Schober, D. Manka, P. von Hundelshausen, Y. Huo, P. Hanrath, and I.J. Sarembock Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury Circulation 106 2002 1523 1529
25. C. Smith, J.K. Damas, K. Otterdal, E. Oie, W.J. Sandberg, and A. Yndestad Increased levels of neutrophil-activating peptide-2 in acute coronary syndromes: possible role of platelet-mediated vascular inflammation J Am Coll Cardiol 48 2006 1591 1599
26. R.E. Ward, J. Woo, and P. Pace Increased release of beta thromboglobulin during acute myocardial infarction Cardiovasc Dis 8 1981 372 378
27. R. Landolfi, E. Scabbia, F. Accorra, L. Cudillo, P. Tanzi, and G. Schiavoni Beta-thromboglobulin in patients with acute and chronic coronary artery disease Acta Cardiol 37 1982 325 332
28. C.W. Pumphrey, and J. Dawes Plasma beta-thromboglobulin as a measure of platelet activity. Effect of risk factors and findings in ischemic heart disease and after acute myocardial infarction Am J Cardiol 50 1982 1258 1261
29. J. Lawler The functions of thrombospondin-1 and-2 Curr Opin Cell Biol 12 2000 634 640
30. Antiplatelet Trialists' Collaboration Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients BMJ 308 1994 81 106
31. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 2002 71 86
32. C. Baigent, L. Blackwell, R. Collins, J. Emberson, J. Godwin, and R. Peto Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials Lancet 373 2009 1849 1860
33. S.A. Harding, J. Sarma, J.N. Din, P.M. Maciocia, D.E. Newby, and K.A. Fox Clopidogrel reduces platelet-leucocyte aggregation, monocyte activation and RANTES secretion in type 2 diabetes mellitus Heart 92 2006 1335 1337
34. G. Montalescot, F. Philippe, A. Ankri, E. Vicaut, E. Bearez, and J.E. Poulard Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial Circulation 98 1998 294 299
35. J.A. van Mourik, R. Boertjes, I.A. Huisveld, K. Fijnvandraat, D. Pajkrt, and P.J. van Genderen von Willebrand factor propeptide in vascular disorders: A tool to distinguish between acute and chronic endothelial cell perturbation Blood 94 1999 179 185
36. J.A. van Mourik, and T. Romani de Wit Von Willebrand factor propeptide in vascular disorders Thromb Haemost 86 2001 164 171
37. K.W. Lee, G.Y. Lip, M. Tayebjee, W. Foster, and A.D. Blann Circulating endothelial cells, von Willebrand factor, interleukin-6, and prognosis in patients with acute coronary syndromes Blood 105 2005 526 532
38. M. Miura, K. Kaikita, M. Matsukawa, K. Soejima, S. Fuchigami, and Y. Miyazaki Prognostic value of plasma von Willebrand factor-cleaving protease (ADAMTS13) antigen levels in patients with coronary artery disease Thromb Haemost 103 2010 623 629
39. S. Kanaji, S.A. Fahs, Q. Shi, S.L. Haberichter, and R.R. Montgomery Contribution of platelet vs. endothelial VWF to platelet adhesion and hemostasis J Thromb Haemost 10 2012 1646 1652
40. G. Montalescot, J.P. Collet, R. Choussat, A. Ankri, and D. Thomas A rise of troponin and/or von Willebrand factor over the first 48 h is associated with a poorer 1-year outcome in unstable angina patients Int J Cardiol 72 2000 293 294
41. M. Schoppet, K.T. Preissner, and L.C. Hofbauer RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function Arterioscler Thromb Vasc Biol 22 2002 549 553
42. A. Vik, E.B. Mathiesen, J. Brox, T. Wilsgaard, I. Njolstad, and L. Jorgensen Serum osteoprotegerin is a predictor for incident cardiovascular disease and mortality in a general population: the Tromso Study J Thromb Haemost 9 2011 638 644
43. T. Omland, T. Ueland, A.M. Jansson, A. Persson, T. Karlsson, and C. Smith Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes J Am Coll Cardiol 51 2008 627 633
44. A.C. Zannettino, C.A. Holding, P. Diamond, G.J. Atkins, P. Kostakis, and A. Farrugia Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor J Cell Physiol 204 2005 714 723
45. S. Shahbazi, P.J. Lenting, C. Fribourg, V. Terraube, C.V. Denis, and O.D. Christophe Characterization of the interaction between von Willebrand factor and osteoprotegerin J Thromb Haemost 5 2007 1956 1962
46. C.J. Boos, B. Balakrishnan, A.D. Blann, and G.Y. Lip The relationship of circulating endothelial cells to plasma indices of endothelial damage/dysfunction and apoptosis in acute coronary syndromes: implications for prognosis J Thromb Haemost 6 2008 1841 1850